Levomethadone; Methadone/Safinamide Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Both of these medicines can increase the level of serotonin in your body.

What might happen:

High serotonin levels may cause changes in body temperature, blood pressure and behavior, leading to a medical condition called Serotonin Syndrome. Serotonin Syndrome may be life threatening.

What you should do about this interaction:

Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together.If you experience muscle twitching, tremors, shivering or stiffness, fever, heavy sweating, heart palpitations, restlessness, confusion, agitation, trouble with coordination, or severe diarrhea contact your doctor right away.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.London DR, Milne MD. Dangers of monoamine oxidase inhibitors. Br Med J 1962 Dec 29;2:1752.
  • 2.Goldberg LI. Monoamine oxidase inhibitors. Adverse reactions and possible mechanisms. JAMA 1964 Nov 2;190(5):456-62.
  • 3.Anonymous. Analgesics and monoamine-oxidase inhibitors. Br Med J 1967 Nov 4;4(574):284.
  • 4.Barry BJ. Adverse effects of MAO inhibitors with narcotics reversed with naloxone. Anaesth Intensive Care 1979 May;7(2):194.
  • 5.Browne B, Linter S. Monoamine oxidase inhibitors and narcotic analgesics. A critical review of the implications for treatment. Br J Psychiatry 1987 Aug;151:210-2.
  • 6.Rossiter A, Souney PF. Interaction between MAOIs and opioids: pharmacologic and clinical considerations. Hosp Formul 1993 Aug;28:692-8.
  • 7.Dolophine (methadone hydrochloride) US prescribing information. Wast-Ward Pharmaceuticals Corp. February 1, 2018.
  • 8.Metharose (methadone hydrochloride) UK summary of product characteristics. Rosemone Pharmaceuticals Limited January 9, 2008.
  • 9.Diskets Dispersible (methadone hydrochloride) US prescribing information. Cebert Pharmaceuticals, Inc. August, 2007.
  • 10.Diamorphine hydrochloride Australian prescribing information. Auralis March 13, 2008.
  • 11.Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005 Mar 17; 352(11):1112-20.
  • 12.FDA (US Food and Drug Administration). FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. available at: http://www.fda.gov/Drugs/DrugSafety/ucm489676.htm March 22, 2016.
  • 13.Xadago (safinamide) US prescribing information. US WorldMeds, LLC March, 2017.
  • 14.Levopidon (levomethadone) Swedish Summary of Product Characteristics. DNE Pharma AS November 30, 2018.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.